- First-in-Human Trial of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein
- 2 Vaccine with Adjuvant of Aluminum Hydroxide and CpG 1018
- 4 Szu-Min Hsieh, M.D.<sup>1</sup>, Wang-Da Liu, M.D.<sup>1</sup>, Yu-Shan Huang, M.D.<sup>1</sup>, Yi-Jiun Lin, Ph.D.<sup>2</sup>,
- 5 Erh-Fang Hsieh, Ph.D.<sup>2</sup>, Wei-Cheng Lian, Ph. D.<sup>2</sup>, Charles Chen, Ad. Prof.<sup>2,3</sup>, I-Chen Tai,
- 6 M.D.<sup>2\*</sup>, Shan-Chwen Chang, M.D., Ph.D.<sup>1\*</sup>
- 7 1. Section of Infectious Diseases, Division of Infectious Diseases, Department of Internal Medicine,
- 8 National Taiwan University Hospital and College of Medicine, National Taiwan University, Taiwan
- 9 <sup>2.</sup> Medigen Vaccine Biologics Corp., Taiwan
- College of Science and Technology, Temple University, Philadelphia, PA 19122, U.S.A.
- \*Corresponding authors

3

17

24

25

- 12 I-Chen Tai, Corresponding Author
- Email: kathytai@medigenvac.com
- 14 Postal address: Medigen Vaccine Biologics Corp.
- 15 7F., No. 16, Ln. 120, Sec. 1, Neihu Rd., Taipei 114, Taiwan
- 16 TEL: +886-2-77450830 #604
- 18 Shan-Chwen Chang, Corresponding Author
- 19 Email: changsc@ntu.edu.tw
- 20 Postal address: National Taiwan University Hospital
- No.7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 100, Taiwan
- 22 TEL: +886-2-23123456#887999
- 23 Keywords: COVID-19 vaccine; CpG 1018; S-2P protein;

26 Abstract 27 Design 28 This is a phase 1, dose-escalation open-label trial to evaluate the safety and 29 immunogenicity of MVC-COV1901, a recombinant stabilized prefusion SARS-CoV-2 spike 30 (S-2P) protein vaccine with adjuvant of aluminum hydroxide and CpG 1018. 31 Methods 32 We enrolled 45 healthy adults from 20 to 49 years of age to be administered with two 33 vaccinations of MVC-COV1901 in a low dose (LD), middle dose (MD), and high dose (HD) 34 of spike protein at 28 days apart. There were 15 participants in each dose group, and all of 35 them were followed up for 28 days after the second vaccination at the time of interim analysis. 36 Adverse events (AEs) and laboratory data were recorded for safety evaluation. Blood samples 37 were collected for wild-type SARS-CoV-2 and pseudovirus neutralization assays as well as 38 SARS-CoV-2 spike-specific immunoglobulin G (IgG) at various times. Overall, the study 39 duration will be 7 months. 40 Results 41 Solicited events were mostly mild and similar in the participants of all three dose groups. 42 No subject experienced fever. There were no serious nor adverse events of special interest at 43 the time point of this interim report. After the second vaccination, the SARS-CoV-2 spike 44 specific IgG titers increased with peak geometric mean titers at 7178.245 (LD), 7746.086

45 (MD), and 11220.58 (HD), respectively. Serum neutralizing activity was detected by two 46 methods in all participants of MD and HD groups, with geometric mean values generally 47 comparable to those of a panel of control convalescent serum specimens. All of the 48 participants in the MD and HD groups were seroconverted after the second vaccination. 49 **Conclusions** 50 The MVC-COV1901 vaccine is safe and elicits remarkable immune responses especially 51 in the MD and HD groups. 52 Trial Registration: ClinicalTrials.gov NCT 04487210 53 54

#### Introduction

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

Human infections due to SARS-CoV-2 began to spread globally following the outbreak in Wuhan, China. WHO panel declared the COVID-19 outbreak as a public health emergency of international concerns, and this outbreak was also subsequently characterized as a pandemic declared by the WHO on March 11<sup>th</sup>, 2020.<sup>1</sup> Approximately 15% of COVID-19 cases are severe that requires oxygen support, and 5% are critical disease with complications such as respiratory failure, acute respiratory distress syndrome (ARDS), sepsis, septic shock, etc.<sup>2</sup> A meta-analysis assessed the risk of underlying diseases in severe patients compared to those in non-severe conditions and showed the pooled odds ratios were 2.36 for hypertension, 2.46 for respiratory system disease, and 3.42 for cardiovascular disease and 2.07 for diabetes.<sup>3</sup> There is currently no cure medication for the potentially lethal COVID-19. Development of a range of vaccines will provide flexibility with prevention strategies. For vaccines intended to generate protective immune response, using an antigen with proper conformation is critical. The neutralizing antibodies induced by spike (S) protein block viruses from binding to their target receptor ACE2 and hence inhibit viral infection. S protein has two major conformational stats, prefusion and postfusion. <sup>4</sup> S-2P protein is a recombinant version of the S protein developed by the laboratory of Dr. Barney S. Graham (Vaccine Research Center, National Institute of Allergy and Infectious Diseases [NIAID], U.S.A.), and is a

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

stabilized prefusion S ectodomain, encoding residues 1–1208 of SARS-CoV-2 spike protein with two proline substitutions at residues 986 and 987, a "GSAS" substitution at residues 682-685 to abolish the furin cleavage site, and a T4 fibritin trimerization motif at the C-terminus.<sup>5</sup> The cryo-electron microscopy structure showed the protein produced by this construct is in the prefusion conformation and can bind to ACE2. <sup>5(p1261)</sup> Similar strategy had been used to retain MERS-COV S protein in the prefusion conformation and demonstrated that stabilized MERS-COV S protein was able to elicit high neutralizing antibody.<sup>6</sup> Medigen's MVC-COV1901 vaccine is formulated as S-2P adjuvanted with Dynavax's CpG 1018 and aluminum hydroxide. CpG 1018 is an oligodeoxynucleotide which acts as a toll-like receptor 9 agonist and has been shown in our preclinical studies to enhance immunogenicity and induce a Th1-skewed immune response<sup>7</sup>. Methods Trial Design This study was a phase 1, prospective, open-label, dose-escalation study to evaluate the safety and immunogenicity of a SARS-CoV-2 vaccine in adults aged 20 to 49 years. The study was commenced at the National Taiwan University Hospital in northern Taiwan from September 2020. The trial protocol and informed consent form were approved by the Taiwan Food and Drug Administration and the ethics committee at the site. The trial was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice.

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

An independent data and safety monitoring board (DSMB) was established to monitor safety data. (ClinicalTrials.gov NCT 04487210) The Investigational Vaccine We applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein, S-2P, designed by Dr. Barney S. Graham (Vaccine Research Center, NIAID, U.S.A.). The MVC-COV1901 contained S-2P protein adjuvanted with CpG 1018 and aluminum hydroxide as previous reported. (pr). The vaccine administered at a volume of 0.5 mL as a single dose via intramuscular injection. The production of the vaccine was conducted in Medigen Vaccine Biologics Corp. facility which is compliant with the current good manufacturing practices (cGMP). **Participants** Eligible participants were healthy adults from 20 to 49 years of age. Eligibility was determined based on medical history, physical examination, laboratory tests, and investigators' clinical judgment. Exclusion criteria included a history of known potential exposure to SARS CoV-1 or 2 viruses, having received any other COVID-19 vaccine, impaired immune function, history of autoimmune disease, abnormal autoantibody tests, febrile or acute illness within 2 days of first dose, and acute respiratory illness within 14 days of first dose.

#### Interventions

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

and Phase 1c would proceed.

This study was a dose escalation study with three separate sub-phases for participants from 20 to 49 years of age. Each sub-phase consisted of 15 participants. The three different dose levels employed in this clinical trial are LD, MD, and HD of S-2P protein adjuvanted with CpG 1018 and aluminum hydroxide for phase 1a, 1b, and 1c, respectively. The vaccination schedule consisted of two doses, administered by intramuscular (IM) injection of 0.5 mL in the deltoid region of non-dominant arm 28 days apart, on Day 1 and Day 29. The protocol permitted an interim analysis to make decisions regarding vaccine strategy. Phase 1a Four sentinel participants would be recruited to receive LD of S-2P protein with adjuvant to evaluate preliminary safety data of the vaccine. If no ≥ Grade 3 AE or SAE occurred within 7 days after the first vaccination in the 4 sentinel participants, dosing of the remaining participants in Phase 1a and Phase 1b would proceed. Phase 1b Another 4 sentinel participants would be enrolled to receive MD of S-2P protein with adjuvant in Phase 1b. If no  $\geq$  Grade 3 AE or SAE occurred within 7 days after the first vaccination in the 4 sentinel participants, dosing of the remaining participants in Phase 1b

Phase 1c

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

Another 4 sentinel participants would be enrolled to receive HD of S-2P protein with adjuvant in phase 1c. If no  $\geq$  Grade 3 AE or SAE occurred within 7 days after the first vaccination in the 4 sentinel participants, dosing of the remaining participants in Phase 1c would proceed. An interim analysis of immunogenicity data and safety data from baseline to 28 days after the second vaccination for all participants were carried out when all of the participants have completed the visit (at 28 days after the second vaccination). Safety Assessment The primary endpoint was to evaluate the safety of MVC-COV1901 in three different strengths (LD, MD, and HD of S-2P protein adjuvanted with CpG 1018 and aluminum hydroxide) from Day 1 to 28 days after the second vaccination. Vital signs and electrocardiogram (ECG) were performed before and after vaccination. Participants were observed for at least 30 min after each vaccination to identify any immediate adverse events (AEs), and were asked to record solicited local and systemic AEs in the participant's diary card for up to 7 days after each vaccination. Unsolicited AEs were recorded for 28 days following each vaccination; all other AEs, serious adverse events (SAEs) and adverse events of special interests (AESIs) were recorded throughout the study period. Serum samples were collected for safety evaluations. Hematology, biochemistry and

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

determined.

immunology tests were measured as well. Immunogenicity Analysis The immunogenicity endpoints were to evaluate the immunogenicity in terms of neutralizing antibody titers and binding antibody titers at 14 days (Day 15) and 28 days (Day 29) after first and at 14 days (Day 43) and 28 days (Day 57) after second vaccination, as well as 90 days and 180 days after the second vaccination. SARS-CoV-2 spike-specific immunoglobulin G (IgG) Total serum anti-Spike IgG titers were detected with direct enzyme-linked immunosorbent assay (ELISA) using customized 96-well plates coated with S-2P antigen. SARS-CoV-2 pseudovirus neutralization assay Pseudovirus production and titration followed the previous report. <sup>7(p7)</sup> Serial dilutions of the samples to be tested were performed (initial dilution of 1:20; diluted two-fold to a final dilution of 1:2560). The diluted serum was mixed with equal volume of pseudovirus (1000 TU) and incubated before adding to the plates with HEK293-hAce2 cells ( $1 \times 10^4$  cells/well). The amount of pseudovirus entering the cells was calculated by lysing and measuring the relative luciferase units (RLU). Fifty percent inhibition dilution (concentration) titers ( $ID_{50}$ ) were calculated considering uninfected cells as 100% neutralization and cells transduced with virus as 0% neutralization and reciprocal ID<sub>50</sub> geometric mean titers (GMT) were both

### Wild $\Box$ type SARS $\Box$ CoV $\Box$ 2 neutralization assay

SARS-CoV-2 virus (hCoV-19/Taiwan/CGMH-CGU-01/2020, GenBank accession MT192759) was obtained and titrated to obtain TCID<sub>50</sub>, and Vero E6 cells ( $2.5 \times 10^4$  cells/well) were seeded in 96-well plates and incubated. The sera underwent a total of 11 two-fold dilutions with the final dilution being 1:8192, and the diluted sera were mixed with equal volume of viral solution containing 100 TCID<sub>50</sub>. The serum-virus mixture was incubated and then added to the cell plates containing the Vero E6 cells, followed by further incubation. The neutralizing titer was defined as the reciprocal of the highest dilution capable of inhibiting 50% of the CPE (NT<sub>50</sub>), which was calculated in accordance with the formula of the Reed-Muench method.

#### **Statistical Analysis**

Safety analysis was performed on the total vaccinated group (TVG) population who received at least 1 dose of vaccine. The endpoints related to immunogenicity consisted of the following: antigen specific immunoglobulins, neutralizing antibody titers of wild type virus and pseudovirus, in terms of geometric mean titer (GMT) and seroconversion rate (SCR). SCR is defined as the percentage of participants with  $\geq$  4-fold increase in titers from the baseline or from half of the lower limit of detection (LoD) if undetectable at baseline.

186 **Results** 187 **Study Population** 188 In total, 77 participants were screened. Of these, 45 eligible participants had completed 189 two doses of MVC-COV1901. Participants' baseline demographic characteristics are 190 summarized in Table 1. 191 **Vaccine Safety** 192 Neither SAEs nor AESI occurred at this time point of interim analysis. No participants 193 missed the second dose. All of the local and systemic AEs were mild, except for one 194 malaise/fatigue in the HD group. None of the participants had fever after either dose 1 or 195 dose 2. Solicited adverse events after the first and the second vaccination were similar. 196 Evaluation of safety laboratory values, ECG interpretation, and unsolicited adverse events 197 revealed no specific concern. 198 **Immunogenicity** 199 The humoral immunogenicity results are summarized in Figure 1. 200 SARS-CoV-2 spike specific immunoglobulin G(IgG)201 Binding IgG titers to S protein increased rapidly after the second vaccination, with 202 seroconversion in all participants by Day 43 and 57. The GMTs peaked at Day 43 with value 203 of 7178.245 (95% CI: 4240.336 ~12151.68), 7746.086 (95% CI: 5530.230 ~10849.79), 204 11220.58 (95% CI: 8592.293 ~14652.84) in LD, MD, HD groups, respectively. The

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

responses in LD, MD, and HD groups were also similar to the values of convalescent serum specimens.(2179.598, [95%CI: 1240.897~3828.396]). (Fig 1A) *Neutralization responses for SARS-CoV-2 pseudovirus* Before vaccination, no subject had detectable pseudovirus neutralizing titers (ID<sub>50</sub>) at the lower limit of serum concentration tested (1:20 dilution) in the assay. At Day 43, the pseudovirus neutralizing titers (ID<sub>50</sub>) showed peaked GMTs of 538.496 (95% CI: 261.9403 ~1107.036), 993.075 (95% CI: 654.9991 ~1505.648), and 1905.840 (95% CI: 1601.667 ~2267.779) in LD, MD, and HD groups, respectively. All of the participants in three doses were seroconverted after the second vaccination (Fig 1B). Neutralization responses for wild type SARS-CoV-2 virus Before vaccination, no subject had detectable wild-type virus neutralizing titers (NT<sub>50</sub>) at the lower limit of serum concentration tested (1:8 dilution) in the assay. However, after the second vaccination, neutralizing responses were identified in serum samples from all participants in MD and HD groups. At Day 43, the GMTs were 33.317 (95% CI: 18.5239 ~59.9256), 76.307 (95% CI: 53.7497 ~108.3309), and 167.402 (95% CI: 122.0492 ~229.6090) in LD, MD, and HD groups, respectively. The MD and HD groups were similar in terms of GMT (52.205 [95% CI: 37.9448 ~71.8246] and 81.909 [95% CI: 55.8131 ~120.2070], respectively, at Day 57). These responses were also similar to the value of convalescent serum specimens. (42.674, [95%CI: 26.37666~69.0403]) All participants in MD

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

and HD groups were seroconverted at Day 43 and Day 57. The results of wild-type SARS-CoV-2 neutralizing antibody titer are summarized in Fig 1C. **Discussion** This is the first clinical trial report to address the protein-based vaccine using the S-2P protein developed by NIAID, U.S.A. as the antigen, and adjuvanted with CpG 1018 and aluminum hydroxide. This interim analysis demonstrated that the MVC-COV1901 vaccine was well tolerated and immunogenic in healthy adults aged 20 to 49 years. Across the three dose groups, local injection-site reactions were all mild. This safety profile is similar to that described in the previous report for subunit protein vaccines adjuvanted with CpG 1018 or aluminum hydroxide.<sup>8,9</sup> With regards to the occurrence rate and severity of solicited AEs, no differences were noticed among the LD, MD, and HD groups, or between the first and second vaccination. The rates of detectable neutralizing response in all three dose groups at baseline were 0%, aligning with the fact that there was no circulating SARS-CoV-2 in Taiwan. The neutralizing antibody titers were measurable at Day 43 and Day 57 for all dose levels. All participants in MD and HD groups were seroconverted in terms of wild-type SARS-CoV-2 neutralizing response. Besides, the wild type neutralizing antibody response profile also demonstrated a good correlation with IgG and pseudovirus neutralizing antibody titers.

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

Although the correlation of protection is not available at present, serum neutralizing activity has been shown to be correlate of protection for other viruses while developing vaccines, such as yellow fever vaccine, polio vaccine, and Japanese encephalitis vaccine, <sup>10</sup> and is generally accepted as a useful biomarker of the in vivo humoral response. Besides, the preclinical study of MVC-COV1901<sup>11</sup> had shown that hamsters were protected from SARS-CoV-2 virus challenge after two vaccinations of S-2P protein adjuvanted with CpG and aluminum hydroxide. The geometric mean titers in the MD and HD groups were comparable with those of a panel of control convalescent serum specimens with all participants in both groups seroconverted after two vaccinations. Therefore, a MD of S-2P combined with CpG 1018 and aluminum hydroxide was deemed adequate to elicit a profound humoral immune response. This interim report has some limitations: small size of the trial, the short period of follow-up at this time point, and the participants' young age and good health status. We were not able to assess the durability of the immune responses after Day 57 in this interim report. However, participants will be followed up for 6 months after the second vaccination with scheduled blood collections throughout that period to evaluate the humoral immunologic responses. Although the level of immunity needed to protect from COVID-19 remains unknown, NIBSC 20/130 standard serum was tested in terms of wild-type SARS-CoV-2 neutralizing antibody titer for the development and evaluation of serological assays for the

detection of antibodies against SARS-CoV-2, as a positive control.

These safety and immunogenicity findings support further advancement of the MVC-COV1901 vaccine to subsequent clinical trials. Of the three doses evaluated, both the MD and HD elicited high neutralizing antibody responses with all participants seroconverted after second vaccination. Further phase 2 trial with 3700 participants (including the populations at greatest risk for serious Covid-19 such as those with chronic medical diseases and older adults) is on-going (ClinicalTrials.gov number, NCT04695652)

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

Acknowledgements Author contributions SM Hsieh, SC Chang and IC Tai had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. SC Chang and IC Tai contributed equally and are joint corresponding authors. Concept and design: SM Hsieh and IC Tai Acquisition, or interpretation of data: SM Hsieh, SC Chang, WD Liu, and YS Huang Drafting and preparing the manuscript: SM Hsieh, SC Chang, WD Liu, YS Huang, YJ Lin, EF Hsieh, and IC Tai Critical revision of the manuscript for important intellectual content: SM Hsieh, SC Chang Laboratory assays set up and analysis of data: YJ Lin, and EF Hsieh Administrative, technical, or material support: Charles Chen and WC Lian All authors reviewed and approved of the final version of the manuscript. Conflict of interests Disclosure Szu-Min Hsieh, Shan-Chwen Chang, Wang-Da Liu, Yu-Shan Huang declared that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper; Yi-Jiun Lin, Erh-Fang Hsieh, Wei-Cheng Lian, Charles Chen, I-Chen Tai reported grants from Taiwan Centers for Disease Control, Ministry of Health and Welfare, during the conduct of the study. In addition, Yi-Jiun Lin and Charles

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

Chen have a patent US63/040,696 pending. Funding/Support Taiwan Centers for Disease Control, Ministry of Health and Welfare provided grant funding for this study, but does not necessarily stand by any commentary made in this paper. Medigen Vaccine Biologics Corp. was the study sponsor and manufacturer of the investigational vaccine, and co-designed the trial, provided the study product, and coordinated interactions with regulatory authorities. The sponsors used contract clinical research organization to oversee clinical site operations. Data were collected by the clinical site research staff, managed by a contract research organization data management team, monitored by a contract research organization, and overseen by the sponsor and an independent data and safety monitoring board. The interim analysis was performed by the contract research organization. Data interpretation, manuscript preparation were performed by the authors and the decision to submit the manuscript for publication was made by the authors. Additional Contributions All the participants for their dedication to this trial; Dr. Barney S. Graham at Vaccine Research Center, National Institute of Allergy and Infectious Diseases, U.S.A., team members at Dynavax Technologies, Emeryville, CA 94608, USA. and Tsun ☐ Yung Kuo at Department of Biotechnology and Animal Science, National Ilan University, Ilan, Taiwan for

309

310

311

312

313

314

315

316

317

318

319

320

321

providing technical guidance and helpful advice; The investigational staff at National Taiwan University Hospital, Taiwan and A2 Healthcare Taiwan Corp. for the conduction of the trial; Leo Lee, Tzay Huar Hong, Hui-Yi Wang, Chian-En Lien, Hao-Yuan Cheng and at Medigen Vaccine Biologics Corp. for collaboration on protocol development, significant contribution to the Investigational New Drug (IND) application, and participation in weekly meeting with the regulatory authority; The members of the safety monitoring committee; Dr. Yu-Chi Chou and his team members at the RNAi Core Facility, Academia Sinica for the pseudovirus neutralization assay; Dr. Shin-Ru Shih at Chang Gung University, Taoyuan, Taiwan and Dr. Chung ☐ Guei Huang as well as her team members at Chang Gung Memorial Hospital, Taoyuan, Taiwan for the wild type SARS-CoV-2 neutralization assay; Team members at Protech Pharmaservices Corporation for spike specific IgG ELISA assay. Dr. Chia En Lien, Dr. Meei-Yun Lin, Luke Tzu-Chi Liu, and Meng-Ju Tsai at Medigen Vaccine Biologics Corp., Taiwan for manuscript editing and revision.

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

References 1. World Health Organization. WHO Director-General's opening remarks at the mission briefing on COVID-19—11 March 2020. World Health Organization. March 11, 2020. Accessed March 3, 2021. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-rem arks-at-the-media-briefing-on-covid-19---11-march-2020 2. World Health Organization. COVID-19 Clinical management: living guidance, 25 January 2021. World Health Organization. January 25, 2021. Accessed March 3, 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 3. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95. doi:10.1016/j.ijid.2020.03.017 4. Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945-946. doi:10.1126/science.abb8923 5. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-1263. doi:10.1126/science.abb2507

6. Pallesen J, Wang N, Corbett KS, et al. Immunogenicity and structures of a rationally

340 designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 341 2017;114(35):E7348-E7357. doi:10.1073/pnas.1707304114 342 7. Kuo TY, Lin MY, Coffman RL, Campbell JD, Traquina P, Lin YJ, Liu LT, Cheng J, Wu 343 YC, Wu CC, Tang WH, Huang CG, Tsao KC, Chen C. Development of CpG-adjuvanted 344 stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci 345 Rep. 2020 Nov 18;10(1):20085. doi: 10.1038/s41598-020-77077-z. PMID: 33208827; 346 PMCID: PMC7676267. 347 8. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]. Package insert. 348 Dynavax Technologies Corporation; 2020. 349 9. Mullen GE, Ellis RD, Miura K, et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 350 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One. 351 2008;3(8):e2940. Published 2008 Aug 13. doi:10.1371/journal.pone.0002940 352 10. U.S. Food and Drug Administration. Table of Surrogate Endpoints That Were the Basis of 353 Drug Approval or Licensure. U.S. Food and Drug Administration. August 20, 2020. 354 Accessed March 3, 2021. 355 https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-356 drug-approval-or-licensure 357 11. CE Lien, YJ Lin, TY Kuo, et al. CpG-adjuvanted stable prefusion SARS-CoV-2 spike 358 protein protected hamsters from SARS-CoV-2 challenge. BioRxiv. Published online

January 7, 2021. doi: <a href="https://doi.org/10.1101/2021.01.07.425674">https://doi.org/10.1101/2021.01.07.425674</a>

359

# Figure

360


361

362


363

364

## A. SARS-CoV-2 spike-specific IgG



## B. SARS-CoV-2 pseudovirus neutralization



### C. Wild-type SARS-CoV-2 neutralization




Fig 1. Summary of Humoral Immune Response

Sera of participants vaccinated with LD, MD, or HD of MVC-COV1901 were measured for anti-spike IgG by (A) ELISA, and neutralization titers were measured by (B) pseudovirus

neutralization assay or (C) live virus neutralization assay. Human convalescent sera (HCS) from 35 recovered COVID-19 patients were analysed by the same assays for comparison and NIBSC 20/130 standard was used in the live virus neutralization assay as a standard (asterisk in panel C). Bars indicate geometric mean titers and error bars indicate 95% confidence intervals. A: The GMTs at Day 43 in terms of SARS-CoV-2 spike specific IgG were 7178.245 (LD), 7746.086 (MD), 11220.58 (HD), and 2179.598 (HCS); B: The GMTs at Day 43 in terms of SARS-CoV-2 pseudovirus ID<sub>50</sub> were 538.496 (LD), 993.075 (MD), 1905.840 (HD), and 430.468 (HCS); C: The GMTs at Day 43 in terms of wild type SARS-CoV-2 NT<sub>50</sub> were 33.317 (LD), 76.307 (MD), 167.402 (HD), and 42.674 (HCS). The value of NIBSC 20/130 standard was 281.84. (as shown in asterisk)

## 377 Tables

378

379

# Table 1. Demographic Characteristics of Eligible Participants

Demographic characteristics	LD	MD	HD	Total
No. of Participants	15	15	15	45
Age				
Mean (SD), years	36.7 (8.97)	33.3 (8.03)	31.5 (5.78)	33.8 (7.84)
Gender				
Male, No. (%)	7 (46.7%)	9 (60.0%)	12 (80.0%)	28 (62.2%)
Female, No. (%)	8 (53.3%)	6 (40.0%)	3 (20.0%)	17 (37.8%)
BMI (kg/m <sup>2</sup> )				
Mean (SD)	23.18 (3.394)	23.30 (3.084)	23.17 (2.429)	23.22 (2.928)